henhaobio
Sign in

Abstract

Many detection methods have been used or reported for the diagnosis and/or surveillance of COVID-19. Among them, reverse transcription polymerase chain reaction (RT-PCR) is the most commonly used because of its high sensitivity, typically claiming detection of about 5 copies of viruses. However, it has been reported that only 47-59% of the positive cases were identified by some RT-PCR methods, probably due to low viral load, timing of sampling, degradation of virus RNA in the sampling process, or possible mutations spanning the primer binding sites. Therefore, alternative and highly sensitive methods are imperative. With the goal of improving sensitivity and accommodating various application settings, we developed a multiplex-PCR-based method comprised of 343 pairs of specific primers, and demonstrated its efficiency to detect SARS-CoV-2 at low copy numbers. The assay produced clean characteristic target peaks of defined sizes, which allowed for direct identification of positives by electrophoresis. We further amplified the entire SARS-CoV-2 genome from 8 to half a million viral copies purified from 13 COVID-19 positive specimens, and detected mutations through next generation sequencing. Finally, we developed a multiplex-PCR-based metagenomic method in parallel, that required modest sequencing depth for uncovering SARS-CoV-2 mutational diversity and potentially novel or emerging isolates.

Abstract summary

Claude Opus 5.5 · xhigh effort · 2 Nov 2026 · from the abstract · CC BY-NC-ND 4.0

A 343-primer-pair multiplex PCR assay enables electrophoretic detection and full-genome sequencing of SARS-CoV-2 across 8 to half a million viral copies from 13 clinical specimens.

Although standard reverse transcription polymerase chain reaction (RT-PCR) assays claim sensitivity down to about 5 viral copies, some RT-PCR methods identify only 47-59% of positive COVID-19 cases, likely due to low viral load, sampling timing, RNA degradation, or possible primer-site mutations. This 343-primer-pair multiplex-PCR assay and parallel metagenomic workflow enable low-copy detection by electrophoresis and full-genome mutation profiling by next-generation sequencing.

Key results

  1. ShownA multiplex-PCR assay using 343 specific primer pairs detects SARS-CoV-2 at low copy numbers and produces defined-size target peaks for direct positive identification by electrophoresis.

    Uses 343 primer pairs yielding characteristic electrophoretic target peaks; exact limit of detection in copy numbers is not stated in the abstract. · Abstract

  2. ShownThe multiplex-PCR enrichment coupled with next-generation sequencing amplified the complete SARS-CoV-2 genome and detected viral mutations across clinical specimens spanning wide viral loads.

    Evaluated on 13 COVID-19-positive specimens containing from 8 to half a million purified viral copies. · Abstract

  3. ClaimedA parallel multiplex-PCR-based metagenomic method uncovers SARS-CoV-2 mutational diversity and candidate emerging isolates at modest sequencing depth.

    Qualitative report of parallel metagenomic assay performance; exact sequencing depth and read counts are not reported in the abstract. · Abstract

Methods, data and reproducibility

A multiplex-PCR assay of 343 SARS-CoV-2-specific primer pairs was developed for direct electrophoretic detection of defined-size target peaks and full-genome enrichment prior to next-generation sequencing. Full-genome amplification and mutation calling were validated on 13 COVID-19-positive specimens (8 to half a million viral copies), alongside a parallel multiplex-PCR metagenomic workflow.

  • Purified viral RNA samples from COVID-19 positive clinical specimens (8 to half a million viral copies) · SARS-CoV-2, human · n = 13 specimens
Reproducibility gaps
Primer sequences, sequencing data accessions, and analysis pipelines are not provided in the abstract.
Limitations (2)
  • Clinical validation of full-genome amplification and sequencing was conducted on a small cohort of 13 COVID-19-positive specimens. · noted in this summary
  • Abstract only; primer sequences, genome coverage percentages, specific mutations detected, and sequencing depth metrics are not reported. · noted in this summary

Read this if you are developing sensitive diagnostic or whole-genome amplicon sequencing assays for low-copy SARS-CoV-2 clinical samples.

Citations
45

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.

Similarity Map
SelectedSame fieldCross-field
THISDurand '21Kudo '20Zhen '20Vanaerschot '20Bhoyar '21Toptan '20
76% semantic matchGenetic & Genomic Medicine
Mathieu Durand, Philippe Thibault, Simon Lévesque+5 more·Microbial Cell·Dec 28, 2021· 7 citations